Shares of Soleno Therapeutics (NASDAQ:SLNO) fell on Wednesday after a federal database indicated that a 17-year-old male treated with the company’s recently launched rare disease therapy Vykat XR had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results